Search Within

Lymphoma

Formats
  1. Meeting Abstract (1382)
  2. Journal Article (1057)
  3. Book Section (64)
  4. Review (64)
  5. Editorial (38)
  6. Research Letter (38)
  7. Guidelines (19)
  8. Conference Paper (15)
  9. Correspondence (12)
  10. Miscellaneous (5)
  11. Book Whole (4)
Groups
  1. Center for Hematologic Malignancies (2698)
  2. Department of Medicine (2698)
  3. Hematologic Malignancies, Division of (2698)
  4. Population Sciences Research Program (744)
  5. Survivorship Research (655)
  6. Executive Committee, Center for Hematologic Malignancies (391)

More Groups

People
  1. Andrew Zelenetz (782)
  2. Steven Horwitz (666)
  3. Maria Palomba (445)
  4. Ariela Noy (371)
  5. David Straus (360)
  6. Alison Moskowitz (358)

More People

Years
  1. 2025 (45)
  2. 2024 (141)
  3. 2023 (180)
  4. 2022 (170)
  5. 2021 (171)
  6. 2020 (170)

More Years

Publications
  1. Blood (876)
  2. Journal of Clinical Oncology (277)
  3. Hematological Oncology (110)
  4. Leukemia and Lymphoma (83)
  5. British Journal of Haematology (81)
  6. Haematologica (71)

More Publications

Publishers
  1. American Society of Hematology (941)
  2. American Society of Clinical Oncology (293)
  3. Elsevier Inc. (187)
  4. Wiley Blackwell (174)
  5. John Wiley & Sons (96)
  6. Nature Publishing Group (93)

More Publishers

Results (2698)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL)
    Meeting Abstract

    Pro, B.; Horwitz, S. M.; Prince, H. M.; Foss, F. M.; Sokol, L.; Greenwood, M.; Caballero, D.; Morschhauser, F.; Wilhelm, M.; Pinter-Brown, L.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Clinical activity of duvelisib (IPI-145), a phosphoinositide-3-kinase-δ,γ inhibitor, in patients previously treated with ibrutinib
    Meeting Abstract

    Porcu, P.; Flinn, I.; Kahl, B. S.; Horwitz, S. M.; Oki, Y.; Byrd, J. C.; Sweeney, J.; Allen, K.; Faia, K.; Ni, M.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Patient characteristics and initial treatment patterns in the United States for the most common subtypes of peripheral T-cell lymphoma (PTCL)
    Meeting Abstract

    Pinter-Brown, L.; Foss, F. M.; Carson, K. R.; Horwitz, S. M.; Rosen, S. T.; Pro, B.; Federico, M.; Gisselbrecht, C.; Hsi, E. D.; Shustov, A. R.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • A comprehensive clinical next generation sequencing-based assay can impact hematopathologic diagnosis in a significant subset of patients with hematologic malignancies
    Meeting Abstract

    Pichardo, J. D.; Feldstein, J. T.; Arcila, M.; Batlevi, C.; Zelenetz, A. D.; Moskowitz, C. H.; Horwitz, S. M.; Tallman, M. S.; Stein, E. M.; Klimek, V. M.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • A phase I open-label, multi-dose escalation study of the dual Syk/Jak inhibitor PRT062070 (cerdulatinib) in patients with relapsed/refractory B cell malignancies
    Meeting Abstract

    Patel, M.; Hamlin, P.; Strickland, D. K.; Pandey, A.; Coffey, G.; Leeds, J. M.; Levy, G. G.; Curnutte, J. T.; Wagner-Johnston, N.; Flinn, I. W.
    Blood (2014)

    Fulltext@MSK | Save
  • Dose-adjusted EPOCH plus /- rituximab in older patients with high grade diffuse large B-cell lymphoma, Burkitt and T-cell lymphoma: An effective regimen with acceptable toxicity profile
    Meeting Abstract

    Owens, C. N.; Migliacci, J. C.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; Younes, A.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma
    Meeting Abstract

    Oki, Y.; Fanale, M. A.; Romaguera, J. E.; Fayad, L.; Fowler, N.; Copeland, A. R. M.; Samaniego, F.; Kwak, L. W.; Neelapu, S. S.; Wang, M.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Duvelisib (IPI-145), a PI3K-δ,γ inhibitor, is clinically active in patients with relapsed/refractory chronic lymphocytic leukemia
    Meeting Abstract

    O'Brien, S.; Patel, M.; Kahl, B. S.; Horwitz, S. M.; Foss, F. M.; Porcu, P.; Sweeney, J.; Allen, K.; Faia, K.; Stern, H. M.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Update on a phase 2 study of idelalisib in combination with rituximab in treatment-naive patients ≥ 65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
    Meeting Abstract

    O'Brien, S.; Lamanna, N.; Kipps, T. J.; Flinn, I. W.; Zelenetz, A. D.; Burger, J. A.; Holes, L. M.; Cho, Y. J.; Dubowy, R. L.; Coutre, S. E.
    Blood (2014)

    Fulltext@MSK | Save
  • Interim analysis of a phase 1 study of the antibody-drug conjugate SGN-CD19A in relapsed or refractory B-lineage non-Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, C. H.; Forero-Torres, A.; Shah, B. D.; Advani, R.; Hamlin, P.; Kim, S.; Kostic, A.; Sandalic, L.; Zhao, B. T.; Fanale, M. A.
    Blood (2014)

    Fulltext@MSK | Save